At Last: Acadia Submits NDA, Makes Davis Permanent CEO
This article was originally published in Scrip
Executive Summary
Following delay after delay, Acadia Pharmaceuticals finally submitted a new drug application (NDA) to the US FDA seeking approval for Nuplazid (pimavanserin) nearly three years after the company reported positive Phase III results in the treatment of Parkinson's disease psychosis (PDP).
You may also be interested in...
Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Need a specific report? 1000+ reports available
Buy Reports